<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02791906</url>
  </required_header>
  <id_info>
    <org_study_id>823665</org_study_id>
    <nct_id>NCT02791906</nct_id>
  </id_info>
  <brief_title>Targeting Central Pulsatile Hemodynamics in Chronic Kidney Disease</brief_title>
  <official_title>Targeting Central Pulsatile Hemodynamics in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <brief_summary>
    <textblock>
      Heart failure (HF) is an epidemic and is a major burden on the US healthcare system. The most&#xD;
      common cardiovascular endpoint is HF. Thus, novel interventions to prevent HF in chronic&#xD;
      kidney disease (CKD) are highly desirable. This study will assess: the variability in the&#xD;
      response to isosorbide mononitrate (ISMN) therapy; the degree of change in central&#xD;
      hemodynamics and cardiac endpoints through analysis of changes in left ventricle (LV) mass,&#xD;
      diffuse myocardial fibrosis, and myocardial systolic and diastolic function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a open label, parallel arm, randomized study of ISMN with or without vitamin C to&#xD;
      improve exercise capacity and LV remodeling in CKD. Twenty subjects with CKD will be enrolled&#xD;
      in this study and three different daily doses of sustained release isosorbide mononitrate&#xD;
      (SR-ISMN) will be administered over time accompanied by a random administration of vitamin C&#xD;
      in half of the subjects (500 mg three times daily). Before administration of SR-ISMN,&#xD;
      baseline assessments will be performed. These include arterial tonometry, Doppler&#xD;
      echocardiography, reflection magnitude measurements, a bicycle exercise test, activity&#xD;
      monitoring, cardiac MRI, 24-hour blood pressure monitoring, and blood drawing. After these&#xD;
      assessments, a dose of 30 mg of SR-ISMN will be administered daily (either with or without&#xD;
      vitamin C) for the first week, 60 mg SR-ISMN for the second week, and 120 mg for the third&#xD;
      week. After each week, blood pressure and central hemodynamics will be assessed. The third&#xD;
      week visit also includes the bicycle exercise study and initiating the long term dose (60 or&#xD;
      120 mg) of SR-ISMN. In the long-term phase, blood pressure and hemodynamics are assessed at&#xD;
      12-weeks post initiation of the study medication(s). After 24 weeks we will perform the final&#xD;
      assessment, which includes the same tests performed during the baseline assessment.&#xD;
      Enrollment will take place at the Hospital of the University of Pennsylvania and the Penn&#xD;
      Presbyterian Medical Center.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of funding&#xD;
  </why_stopped>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in LV Mass</measure>
    <time_frame>Measured at Baseline Visit and 24 Week Visit</time_frame>
    <description>Variability seen in change in LV mass with ISMN administration measured with steady-state free precession cardiac MRI, outcomes reflect the change, in grams</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Diffuse Myocardial Fibrosis</measure>
    <time_frame>Measured at Baseline Visit and 24 Week Visit</time_frame>
    <description>Myocardial ECV was assessed using a modified Look-Locker inversion recovery sequence to assess T1 times before and following the IV administration of gadolinium contrast in a mid-ventricular short-axis slice. Parameters for modified Look-Locker inversion recovery were: field of view=340mm2; matrix size=144×192; slice thickness=6mm; repetition time=2.4ms; echo time=1.18ms; flip angle=30 degrees, bandwidth=1000 Hz/pixel, integrated parallel acquisition techniques=2. Myocardial T1measurements were performed before and at several time points (5, 10, 15, and 20-40 min) post-gadolinium administration. Modified Look-Locker inversion recovery was performed with a 5-3-3 schema with (2 inversions, 5 echo times after inversion 1, 3 T1 recovery heartbeats, and 3 echo times after inversion 2). All T1 measurements were used to compute lambda (the myocardium-blood partition coefficient) as the slope of the myocardial 1/T1 over the blood 1/T1 change, by linear regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Myocardial Systolic and Diastolic Function</measure>
    <time_frame>Measured at Baseline Visit and 24 visits</time_frame>
    <description>Variability in changes in myocardial function with ISMN administration, assessed via systolic longitudinal strain (measured with tissue tracking MRI) with adequate data for tissue tracking. Strain is the shortening during contraction, expressed as a promotion of the end-diastolic myocardial length. Shortening is indicated by a negative value. Strain is a unit-less metric and is thus expressed in %. A change with negative sign indicates more pronounced shortening of baseline compared to 6 months; a change with positive sign indicates less pronounced shortening during contraction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Wave Reflection Magnitude</measure>
    <time_frame>Measured between Baseline Visit-Week 24</time_frame>
    <description>Measured by arterial tonometry and echocardiography. The data reflects estimated changes in each group utilizing all available measurements, collected at all timepoints (baseline visit and weeks 1, 2, 3, 12, and 24 visits). Numbers are estimated changes in each group utilizing available measurements. The change represents the absolute change in the ratio of backward to forward wave amplitudes, multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aerobic Capacity</measure>
    <time_frame>Change from Baseline at Week 24 reported</time_frame>
    <description>Variability in changes in aerobic capacity (peak oxygen consumption during maximal supine bicycle exercise test)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>ISMN Only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive only ISMN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISMN AND Vitamin C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive both ISMN and Vitamin C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISMN</intervention_name>
    <arm_group_label>ISMN AND Vitamin C</arm_group_label>
    <arm_group_label>ISMN Only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <arm_group_label>ISMN AND Vitamin C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic kidney disease stage 3&#xD;
&#xD;
          -  Elevated left ventricular mass index or LV posterior wall thickness &gt;1.4 cm documented&#xD;
             in a clinically indicated echocardiographic or MRI examination within the previous 24&#xD;
             months or electrocardiographic LV hypertrophy&#xD;
&#xD;
          -  Stable medical therapy as defined by no addition, removal or change in dosage &gt;100% of&#xD;
             Angiotensin-converting-enzyme (ACE) inhibitors, angiotensin receptor blockers,&#xD;
             beta-blockers, or calcium channel blockers for &gt; 30 days&#xD;
&#xD;
          -  Current therapy with an ACE inhibitor, hydralazine or a statin, all of which have been&#xD;
             shown to reduce nitrate tolerance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A clinically- indicated stress test demonstrating significant myocardial ischemia&#xD;
             within 1 year of enrollment, not followed by coronary revascularization&#xD;
&#xD;
          -  Rhythm other than sinus (i.e., atrial fibrillation)&#xD;
&#xD;
          -  Non-cardiac condition limiting life expectancy to &lt;1 year&#xD;
&#xD;
          -  Current or anticipated future need for long acting organic nitrate therapy&#xD;
&#xD;
          -  Severe aortic or mitral valve disease&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Known infiltrative or inflammatory myocardial disease (amyloid, sarcoid)&#xD;
&#xD;
          -  Pericardial disease&#xD;
&#xD;
          -  Primary pulmonary arteriopathy&#xD;
&#xD;
          -  History of myocardial infarction, unstable angina, percutaneous transluminal coronary&#xD;
             angiography (PTCA) or coronary artery bypass grafting (CABG) within 60 days, or&#xD;
             requirement for either PTCA or CABG at the time of consent&#xD;
&#xD;
          -  Resting heart rate (HR) &gt;100 bpm&#xD;
&#xD;
          -  A reduced LV ejection fraction (EF&lt;50%)&#xD;
&#xD;
          -  Known severe liver disease (AST &gt;3x normal, alkaline phosphatase or bilirubin &gt;2x&#xD;
             normal)&#xD;
&#xD;
          -  Allergy to ISMN&#xD;
&#xD;
          -  Current therapy with phosphodiesterase inhibitors, such as sildenafil, vardanafil or&#xD;
             tadalafil&#xD;
&#xD;
          -  Therapy with rosiglitazone&#xD;
&#xD;
          -  Current pregnancy or a positive urine pregnancy test; women who become pregnant during&#xD;
             the study will be discontinued from the trial&#xD;
&#xD;
          -  Therapy with warfarin&#xD;
&#xD;
          -  History of kidney stones&#xD;
&#xD;
          -  History of glucose-6-phosphate dehydrogenase (G6PD) deficiency&#xD;
&#xD;
          -  Systolic blood pressure &lt;110 mmHg or diastolic blood pressure &lt;40 mmHg;&#xD;
&#xD;
          -  Contraindications to a cardiac MRI: (a) Central nervous system aneurysm clips; (b)&#xD;
             Implanted neural stimulators; (c) Implanted cardiac pacemaker or defibrillator; (d)&#xD;
             Cochlear implant; (e) Ocular foreign body (e.g. metal shavings); (f) Other implanted&#xD;
             medical devices: (e.g. drug infusion ports); (g) Insulin pump; (h) Metal shrapnel or&#xD;
             bullet; (i) Claustrophobia; (j) Extreme obesity rendering the patient unable to fit&#xD;
             into narrow-bore scanners; (k) Unwillingness of the patient to undergo a cardiac MRI.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio Chirinos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 26, 2016</study_first_submitted>
  <study_first_submitted_qc>June 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2016</study_first_posted>
  <results_first_submitted>February 27, 2020</results_first_submitted>
  <results_first_submitted_qc>July 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2020</results_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Julio A. Chirinos</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Chronic Kidney Diseases</keyword>
  <keyword>Chronic Kidney Insufficiency</keyword>
  <keyword>Chronic Renal Diseases</keyword>
  <keyword>Chronic Renal Insufficiency</keyword>
  <keyword>Kidney Insufficiency, Chronic</keyword>
  <keyword>Cardiac Failure</keyword>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>Heart Decompensation</keyword>
  <keyword>Heart Failure, Congestive</keyword>
  <keyword>Myocardial Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 15, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT02791906/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Screening was performed from electronic medical records searcesh for potential study participants, followed by manual review.</recruitment_details>
      <pre_assignment_details>After assessing subjects for eligibility via electronic health record reviews (n=529), 522 were excluded due to not meeting inclusion/exclusion criteria (n=506), not being interested in participating upon telephone interview (n=3) and various other reasons (inability to contact, inability to exercise, scheduling difficulties; n=13).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ISMN Only</title>
          <description>Patients receive only ISMN&#xD;
ISMN</description>
        </group>
        <group group_id="P2">
          <title>ISMN AND Vitamin C</title>
          <description>Patients receive both ISMN and Vitamin C&#xD;
ISMN&#xD;
Vitamin C</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ISMN Only</title>
          <description>Patients receive only ISMN&#xD;
ISMN</description>
        </group>
        <group group_id="B2">
          <title>ISMN AND Vitamin C</title>
          <description>Patients receive both ISMN and Vitamin C&#xD;
ISMN&#xD;
Vitamin C</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.75" spread="10.65"/>
                    <measurement group_id="B2" value="64" spread="4.36"/>
                    <measurement group_id="B3" value="64.43" spread="7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in LV Mass</title>
        <description>Variability seen in change in LV mass with ISMN administration measured with steady-state free precession cardiac MRI, outcomes reflect the change, in grams</description>
        <time_frame>Measured at Baseline Visit and 24 Week Visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ISMN Only</title>
            <description>Patients receive only ISMN&#xD;
ISMN</description>
          </group>
          <group group_id="O2">
            <title>ISMN AND Vitamin C</title>
            <description>Patients receive both ISMN and Vitamin C&#xD;
ISMN&#xD;
Vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LV Mass</title>
          <description>Variability seen in change in LV mass with ISMN administration measured with steady-state free precession cardiac MRI, outcomes reflect the change, in grams</description>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.95" spread="31.5"/>
                    <measurement group_id="O2" value="-10.4" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Diffuse Myocardial Fibrosis</title>
        <description>Myocardial ECV was assessed using a modified Look-Locker inversion recovery sequence to assess T1 times before and following the IV administration of gadolinium contrast in a mid-ventricular short-axis slice. Parameters for modified Look-Locker inversion recovery were: field of view=340mm2; matrix size=144×192; slice thickness=6mm; repetition time=2.4ms; echo time=1.18ms; flip angle=30 degrees, bandwidth=1000 Hz/pixel, integrated parallel acquisition techniques=2. Myocardial T1measurements were performed before and at several time points (5, 10, 15, and 20-40 min) post-gadolinium administration. Modified Look-Locker inversion recovery was performed with a 5-3-3 schema with (2 inversions, 5 echo times after inversion 1, 3 T1 recovery heartbeats, and 3 echo times after inversion 2). All T1 measurements were used to compute lambda (the myocardium-blood partition coefficient) as the slope of the myocardial 1/T1 over the blood 1/T1 change, by linear regression.</description>
        <time_frame>Measured at Baseline Visit and 24 Week Visit</time_frame>
        <population>Patients who had measurements at baseline and 24 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>ISMN Only</title>
            <description>Patients receive only ISMN&#xD;
ISMN</description>
          </group>
          <group group_id="O2">
            <title>ISMN AND Vitamin C</title>
            <description>Patients receive both ISMN and Vitamin C&#xD;
ISMN&#xD;
Vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Diffuse Myocardial Fibrosis</title>
          <description>Myocardial ECV was assessed using a modified Look-Locker inversion recovery sequence to assess T1 times before and following the IV administration of gadolinium contrast in a mid-ventricular short-axis slice. Parameters for modified Look-Locker inversion recovery were: field of view=340mm2; matrix size=144×192; slice thickness=6mm; repetition time=2.4ms; echo time=1.18ms; flip angle=30 degrees, bandwidth=1000 Hz/pixel, integrated parallel acquisition techniques=2. Myocardial T1measurements were performed before and at several time points (5, 10, 15, and 20-40 min) post-gadolinium administration. Modified Look-Locker inversion recovery was performed with a 5-3-3 schema with (2 inversions, 5 echo times after inversion 1, 3 T1 recovery heartbeats, and 3 echo times after inversion 2). All T1 measurements were used to compute lambda (the myocardium-blood partition coefficient) as the slope of the myocardial 1/T1 over the blood 1/T1 change, by linear regression.</description>
          <population>Patients who had measurements at baseline and 24 weeks.</population>
          <units>% of myocardial tissue composed of ECV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="4.56"/>
                    <measurement group_id="O2" value="2.12" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Myocardial Systolic and Diastolic Function</title>
        <description>Variability in changes in myocardial function with ISMN administration, assessed via systolic longitudinal strain (measured with tissue tracking MRI) with adequate data for tissue tracking. Strain is the shortening during contraction, expressed as a promotion of the end-diastolic myocardial length. Shortening is indicated by a negative value. Strain is a unit-less metric and is thus expressed in %. A change with negative sign indicates more pronounced shortening of baseline compared to 6 months; a change with positive sign indicates less pronounced shortening during contraction.</description>
        <time_frame>Measured at Baseline Visit and 24 visits</time_frame>
        <population>patients who underwent measurements at baseline and 24 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>ISMN Only</title>
            <description>Patients receive only ISMN&#xD;
ISMN</description>
          </group>
          <group group_id="O2">
            <title>ISMN AND Vitamin C</title>
            <description>Patients receive both ISMN and Vitamin C&#xD;
ISMN&#xD;
Vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Myocardial Systolic and Diastolic Function</title>
          <description>Variability in changes in myocardial function with ISMN administration, assessed via systolic longitudinal strain (measured with tissue tracking MRI) with adequate data for tissue tracking. Strain is the shortening during contraction, expressed as a promotion of the end-diastolic myocardial length. Shortening is indicated by a negative value. Strain is a unit-less metric and is thus expressed in %. A change with negative sign indicates more pronounced shortening of baseline compared to 6 months; a change with positive sign indicates less pronounced shortening during contraction.</description>
          <population>patients who underwent measurements at baseline and 24 weeks</population>
          <units>Percent shortening</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.95" spread="9.67"/>
                    <measurement group_id="O2" value="7.23" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse Wave Reflection Magnitude</title>
        <description>Measured by arterial tonometry and echocardiography. The data reflects estimated changes in each group utilizing all available measurements, collected at all timepoints (baseline visit and weeks 1, 2, 3, 12, and 24 visits). Numbers are estimated changes in each group utilizing available measurements. The change represents the absolute change in the ratio of backward to forward wave amplitudes, multiplied by 100.</description>
        <time_frame>Measured between Baseline Visit-Week 24</time_frame>
        <population>participants with measurements available at baseline and 24 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>ISMN Only</title>
            <description>Patients receive only ISMN&#xD;
ISMN</description>
          </group>
          <group group_id="O2">
            <title>ISMN AND Vitamin C</title>
            <description>Patients receive both ISMN and Vitamin C&#xD;
ISMN&#xD;
Vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Wave Reflection Magnitude</title>
          <description>Measured by arterial tonometry and echocardiography. The data reflects estimated changes in each group utilizing all available measurements, collected at all timepoints (baseline visit and weeks 1, 2, 3, 12, and 24 visits). Numbers are estimated changes in each group utilizing available measurements. The change represents the absolute change in the ratio of backward to forward wave amplitudes, multiplied by 100.</description>
          <population>participants with measurements available at baseline and 24 weeks</population>
          <units>% of change in magnitude</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="6.11"/>
                    <measurement group_id="O2" value="-2.28" spread="8.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aerobic Capacity</title>
        <description>Variability in changes in aerobic capacity (peak oxygen consumption during maximal supine bicycle exercise test)</description>
        <time_frame>Change from Baseline at Week 24 reported</time_frame>
        <population>Only 3 subjects had sufficient data to compute a change from baseline, 1 in the ISMN only arm and 2 in the ISMN + Vit C arm. Below are the results of the data that was analyzed for those subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>ISMN Only</title>
            <description>Monotherapy with isosorbide mononitrate</description>
          </group>
          <group group_id="O2">
            <title>ISMN AND Vitamin C</title>
            <description>Combination therapy with isosorbide mononitrate and vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Aerobic Capacity</title>
          <description>Variability in changes in aerobic capacity (peak oxygen consumption during maximal supine bicycle exercise test)</description>
          <population>Only 3 subjects had sufficient data to compute a change from baseline, 1 in the ISMN only arm and 2 in the ISMN + Vit C arm. Below are the results of the data that was analyzed for those subjects.</population>
          <units>L of O2 consumed/ minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05732" spread="0"/>
                    <measurement group_id="O2" value="0.32813" spread="0.49521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ISMN Only</title>
          <description>Monotherapy with isosorbide mononitrate</description>
        </group>
        <group group_id="E2">
          <title>ISMN AND Vitamin C</title>
          <description>Combination therapy with isosorbide mononitrate and vitamin C</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urosepsis requiring hospitalization</sub_title>
                <description>Participant presented with with bilateral flank pain and chills, acute kidney injury, leukocytosis and E. coli bacteremia. The diagnosis was urosepsis, which was successfully treated with antibiotics.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>2n degree AV block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Ankle swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Heart burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Balance problems</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sleep</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness/dizziness/lightheadedness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening renal AKI + Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Professor</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>2152007779</phone>
      <email>julio.chirinos@uphs.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

